$0.5193
-0.0442-7.84%
Last update: Oct 23, 7:38 PM
Outlook Therapeutics Inc (OTLK) Stock Price, Quote, News & History
OTLKNASDAQ
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
You can purchase shares of Outlook Therapeutics (NASDAQ:OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Outlook Therapeutics has a consensus price target of $9.70.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $0.528 last updated October 23, 2026 at 7:38 PM EDT.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an...
